AOD-9604 vs Semaglutide
AOD-9604 and Semaglutide are both studied for fat loss, but they exist on completely different tiers of clinical evidence. Semaglutide is FDA-approved with extensive phase III data, while AOD-9604 is a synthetic fragment of growth hormone that failed to achieve regulatory approval for obesity despite early promise.
Side-by-Side Comparison
| Category | AOD-9604 | Semaglutide |
|---|---|---|
| Mechanism of action | Fragment of growth hormone (amino acids 177-191) that mimics GH's lipolytic (fat-burning) effects without promoting growth or raising blood sugar. Stimulates lipolysis and inhibits lipogenesis. | GLP-1 receptor agonist. Reduces appetite centrally, slows gastric emptying, enhances insulin secretion, and suppresses glucagon. Comprehensive metabolic effects. |
| Primary research area | Obesity/fat loss (failed phase IIb trial). Also studied for osteoarthritis (achieved TGA listing in Australia for cartilage repair). Limited therapeutic application for weight loss. | Type 2 diabetes (Ozempic), chronic weight management (Wegovy), cardiovascular risk reduction (SELECT trial). Multiple successful phase III programs. |
| Evidence level | Failed phase IIb obesity trial (Metabolic Pharmaceuticals, 2007) — did not demonstrate significant weight loss vs placebo. Listed by Australian TGA for osteoarthritis. Very limited clinical evidence for fat loss. | FDA-approved with extensive phase III data. STEP trials showed ~15-17% body weight loss. SELECT trial showed 20% cardiovascular risk reduction. Gold standard of evidence. |
| Administration route | Subcutaneous injection, daily. | Subcutaneous injection, once weekly. Oral form (Rybelsus) available for diabetes. |
| Typical research dosing | 250-500 mcg daily subcutaneous, typically in the morning on an empty stomach. | Up to 2.4 mg weekly subcutaneous (Wegovy). Gradual dose titration over 16-20 weeks. |
| Key studies/evidence | Metabolic Pharmaceuticals phase IIb (2007) — failed primary endpoint for obesity. Heffernan et al. — mechanism of action studies. Australian TGA listing for osteoarthritis only. | STEP 1-5 trials, SUSTAIN trials, SELECT cardiovascular outcomes trial. Tens of thousands of patients studied. Clear, reproducible weight loss effects. |
Can They Be Stacked?
No evidence-based rationale for combining. Semaglutide alone produces well-documented weight loss. Adding AOD-9604 introduces additional injection burden without proven additive benefit. A healthcare provider is unlikely to recommend this combination given AOD-9604's failed clinical trial.
Verdict
The evidence gap is substantial. Semaglutide is FDA-approved with robust clinical data showing significant weight loss and cardiovascular benefit. AOD-9604 failed its clinical trial for obesity and has no regulatory approval for weight loss anywhere. While AOD-9604 is popular in compounding pharmacies, the clinical evidence does not support it as a credible alternative to semaglutide for fat loss.
Related Comparisons
Semaglutide and Tirzepatide are both FDA-approved for type 2 diabetes and weight management, making them the most evidence-backed peptides available. Semaglutide is a GLP-1 receptor agonist, while Tirzepatide is a dual GIP/GLP-1 receptor agonist -- a key distinction that affects their efficacy profiles.
Semaglutide vs Retatrutide: Dual vs Triple Agonist Weight LossSemaglutide and Retatrutide represent two different generations of incretin-based weight loss therapies. Semaglutide is a GLP-1 receptor agonist with extensive clinical data and FDA approval, while Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activation distinguishes Retatrutide from all currently approved therapies and introduces a thermogenic component that may drive greater fat loss -- but it remains in clinical trials.
Semaglutide vs Tesofensine: Weight Loss ComparisonSemaglutide and Tesofensine represent two fundamentally different pharmacological approaches to weight loss. Semaglutide is a GLP-1 receptor agonist that reduces appetite through gut-brain hormonal signaling -- it is FDA-approved and backed by extensive Phase III clinical data. Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, and dopamine) that suppresses appetite through central nervous system stimulation. Tesofensine reached Phase II trials with impressive weight loss results but has not advanced to Phase III approval due to cardiovascular safety concerns. This comparison examines the evidence, safety profiles, and practical considerations for each.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.